HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival

BMC Neurology

Tao Jiang¹  Zhifeng Wu¹  Xing Fan¹  Jingshan Liang¹  Zheng Wang²  Aimin Li³ 

[1] Beijing Neurosurgical Institute, Capital Medical University;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University;Department of Neurosurgery, Lianyungang First People’s Hospital, Xuzhou Medical University;

关键词: Diffuse glioma;    HLA-E;    Clinical outcome;    Prognostic biomarker;   

DOI  :  10.1186/s12883-020-01640-4

来源: DOAJ

【 摘 要 】

Abstract Background Human leukocyte antigen-E (HLA-E) has been extensively investigated in various human cancers including glioma. However, the clinical significance of HLA-E expression in glioma patients has not been elucidated. The current study aimed to investigate the association of HLA-E expression with clinicopathological features and survival in patients with diffuse glioma. Methods A total of 261 glioma patients were enrolled, subsequently, mRNA microarray analysis was conducted to identify the relationship of HLA-E with clinicopathological features and patient survival. Results HLA-E was significantly overexpressed in high-grade gliomas compared to low-grade gliomas (LGGs). Moreover, HLA-E expression was significantly higher in diffuse astrocytomas than oligodendrogliomas (p = 0.032, t-test). Kaplan-Meier analysis showed that progression-free survival (PFS) and overall survival (OS) were significantly better in LGG patients with low HLA-E expression (p = 0.018 for PFS and p = 0.020 for OS, Log-rank test). Furthermore, HLA-E expression was identified to be an independent prognostic factor by Cox analysis (p = 0.020 for PFS and p = 0.024 for OS). Conclusions This is the first study which identified the clinical significance of HLA-E in diffuse glioma. HLA-E expression was correlated with more aggressive tumor grade and histological type and was identified as an independent prognostic biomarker in LGG patients.

【 授权许可】

Unknown